TRAIL-receptor antibodies as a potential cancer treatment.
TRAIL-receptor antibodies as a potential cancer treatment.
复制标题
DOI：
10.2217/14796694.3.4.405
复制
发表时间：
2007-08-01
期刊：
影响因子：
--
通讯作者：
LoBuglio, Albert F
中科院分区：
文献类型：
--
作者：
Buchsbaum, Donald J;Forero-Torres, Andres;LoBuglio, Albert F
越来越多的注意力集中在使用针对TNF相关凋亡诱导配体（TRAIL）死亡受体DR4或DR5的激动性单克隆抗体作为潜在的癌症治疗。这些抗体对癌细胞具有强的肿瘤诱导活性，对临床前模型中的肿瘤异种移植物具有强效抗肿瘤活性，并通过联合化疗治疗增强。有几种针对DR4和DR5的激动性人源化或人单克隆抗体已在晚期癌症患者的I期和II期试验中进行了测试。这些试验已经证明这些抗体具有良好的耐受性，并产生长期稳定的疾病，这是晚期癌症患者的最佳抗肿瘤效果。正在进行临床研究，其中正在研究TRAIL受体抗体在晚期癌症患者中的联合治疗方案。预期来自广谱癌症治疗临床试验的结果将鉴定TRAIL死亡受体抗体作为单一药剂或与化疗剂或放射疗法组合的活性和毒性概况。
Increasing attention has been focused on the use of agonistic monoclonal antibodies against TNF-related apoptosis-inducing ligand (TRAIL) death receptors DR4 or DR5 as a potential cancer treatment. These antibodies have strong apoptosis-inducing activity against cancer cells and potent antitumor activity against tumor xenografts in preclinical models that are enhanced by combination chemotherapy treatment. There are several agonistic humanized or human monoclonal antibodies against DR4 and DR5 that have been tested in Phase I and II trials in patients with advanced cancer. These trials have demonstrated these antibodies to be well tolerated, and to produce prolonged stable disease, which is the best antitumor effect in patients with advanced cancer. Clinical studies in which TRAIL-receptor antibodies are being investigated in combination treatment regimens in patients with advanced cancer are ongoing. It is anticipated that the results from a broad spectrum of cancer therapy clinical trials will identify the activity and toxicity profiles of TRAIL death-receptor antibodies as a single agent, or in combination with chemotherapy agents or radiation therapy.